Effect of morphine on locomotor activity and striatal monoamine metabolism in nicotine-withdrawn mice

Behavioural Brain Research

Volumn 173, Issue 1, 2006, Pages 85-93

  Vihavainen, Tanja ^a   Mijatovic, Jelena ^a   Piepponen, T Petteri ^a   Tuominen, Raimo K ^a   Ahtee, Liisa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

5 Hydroxytryptamine; Dopamine; Locomotor activity; Morphine; Nicotine; Noradrenaline; Withdrawal

Indexed keywords

COCAINE; DOPAMINE; MORPHINE; NICOTINE; NORADRENALIN; SEROTONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN METABOLISM; CATECHOLAMINE METABOLISM; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; LOCOMOTION; MALE; METABOLIC REGULATION; METABOLITE; MONOAMINE METABOLISM; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PUTAMEN; SEROTONIN METABOLISM; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BIOGENIC MONOAMINES; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; DOPAMINE; DRUG INTERACTIONS; MALE; MICE; MORPHINE; MOTOR ACTIVITY; NARCOTICS; NEOSTRIATUM; NICOTINE; NOREPINEPHRINE; NUCLEUS ACCUMBENS; SEROTONIN; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 33749992304     PISSN: 01664328     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbr.2006.06.004     Document Type: Article

References (61)

1. Ahtee L., Attila L.M., Carlson K.R., and Haikala H. Changes in brain monoamine metabolism during withdrawal from chronic oral self-administration of morphine and in response to a morphine challenge in the withdrawn state. J Pharmacol Exp Ther 249 (1989) 303-310
2. Airavaara M., Mijatovic J., Vihavainen T., Piepponen T.P., Saarma M., and Ahtee L. In heterozygous GDNF knockout mice the response of striatal dopaminergic system to acute morphine is altered. Synapse 59 (2006) 321-329
3. Airio J., and Ahtee L. Role of cerebral dopamine and noradrenaline in the morphine-induced locomotor sensitisation in mice. Pharmacol Biochem Behav 58 (1997) 379-386
4. Airio J., and Ahtee L. The involvement of noradrenergic transmission in the morphine-induced locomotor hyperactivity in mice withdrawn from repeated morphine treatment. Br J Pharmacol 126 (1999) 1609-1619
5. Airio J., Attila M., and Ahtee L. Regional differences in cerebral noradrenaline turnover in mice withdrawn from repeated morphine treatment and tolerance to the effects of acute morphine. Pharmacol Toxicol 77 (1995) 196-203
6. 3H]-dopamine release from rat ventral tegmental area in vitro after chronic nicotine administration. BMC Pharmacol 4 (2004) 24
7. Araki H., Kawakami K.Y., Jin C., Suemaru K., Kitamura Y., Nagata M., et al. Nicotine attenuates place aversion induced by naloxone in single-dose, morphine-treated rats. Psychopharmacology (Berl) 171 (2004) 398-404
8. Attila L.M., and Ahtee L. Retardation of cerebral dopamine turnover after morphine withdrawal and its enhanced acceleration by acute morphine administration in rats. Naunyn Schmiedebergs Arch Pharmacol 327 (1984) 201-207
9. Benowitz N.L. Pharmacology of nicotine: addiction and therapeutics. Annu Rev Pharmacol Toxicol 36 (1996) 597-613
10. 3H]nicotine binding sites in human brain. J Neurochem 50 (1988) 1243-1247
11. Berrendero F., Kieffer B.L., and Maldonado R. Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in μ-opioid receptor knock-out mice. J Neurosci 22 (2002) 10935-10940
12. Berrendero F., Mendizabal V., Robledo P., Galeote L., Bilkei-Gorzo A., Zimmer A., et al. Nicotine-induced antinociception, rewarding effects, and physical dependence are decreased in mice lacking the preproenkephalin gene. J Neurosci 25 (2005) 1103-1112
13. Biala G., and Weglinska B. Calcium channel antagonists attenuate cross-sensitization to the rewarding and/or locomotor effects of nicotine, morphine and MK-801. J Pharm Pharmacol 56 (2004) 1021-1028
14. Bläsig J., and Herz A. Interactions of opiates and endorphins with cerebral catecholamines. In: Szekeres L. (Ed). Handbook of experimental pharmacology, part I. 1st ed. (1980), Springer-Verlag, Berlin, Heidelberg 463-497
15. Brauer L.H., Behm F.M., Westman E.C., Patel P., and Rose J.E. Naltrexone blockade of nicotine effects in cigarette smokers. Psychopharmacology (Berl) 143 (1999) 339-346
16. Dhatt R.K., Gudehithlu K.P., Wemlinger T.A., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Preproenkephalin mRNA and methionine-enkephalin content are increased in mouse striatum after treatment with nicotine. J Neurochem 64 (1995) 1878-1883
17. Di Chiara G., and Imperato A. Opposite effects of mu and kappa opiate agonists on dopamine release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Ther 244 (1988) 1067-1080
18. Fadda P., Scherma M., Fresu A., Collu M., and Fratta W. Dopamine and serotonin release in dorsal striatum and nucleus accumbens is differentially modulated by morphine in DBA/2J and C57BL/6J mice. Synapse 56 (2005) 29-38
19. Gäddnäs H., Pietilä K., Piepponen T.P., and Ahtee L. Enhanced motor activity and brain dopamine turnover in mice during long-term nicotine administration in the drinking water. Pharmacol Biochem Behav 70 (2001) 497-503
20. Garcia-Sevilla J.A., Ahtee L., Magnusson T., and Carlsson A. Opiate-receptor mediated changes in monoamine synthesis in rat brain. J Pharm Pharmacol 30 (1978) 613-621
21. Gardner E.L., and Ashby Jr. C.R. Heterogeneity of the mesotelencephalic dopamine fibers: physiology and pharmacology. Neurosci Biobehav Rev 24 (2000) 115-118
22. Glick S.D., Maisonneuve I.M., Kitchen B.A., and Fleck M.W. Antagonism of a3β4 nicotinic receptors as a strategy to reduce opioid and stimulant self-administration. Eur J Pharmacol 438 (2002) 99-105
23. Hildebrand B.E., Nomikos G.G., Hertel P., Schilström B., and Svensson T.H. Reduced dopamine output in the nucleus accumbens but not in the medial prefrontal cortex in rats displaying a mecamylamine-precipitated nicotine withdrawal syndrome. Brain Res 779 (1998) 214-225
24. Houdi A.A., Dasgupta R., and Kindy M.S. Effect of nicotine use and withdrawal on brain preproenkephalin A mRNA. Brain Res 799 (1998) 257-263
25. Ise Y., Narita M., Nagase H., and Suzuki T. Modulation of opioidergic system on mecamylamine-precipitated nicotine-withdrawal aversion in rats. Psychopharmacology (Berl) 151 (2000) 49-54
26. Isola R., Zhang H., Duchemin A.M., Tejwani G.A., Neff N.H., and Hadjiconstantinou M. Met-enkephalin and preproenkephalin mRNA changes in the striatum of the nicotine abstinence mouse. Neurosci Lett 325 (2002) 67-71
27. Johnson S.W., and North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci 12 (1992) 483-488
28. King A.C., and Meyer P.J. Naltrexone alteration of acute smoking response in nicotine-dependent subjects. Pharmacol Biochem Behav 66 (2000) 563-572
29. Kuschinsky K., and Hornykiewicz O. Effects of morphine on striatal dopamine metabolism: possible mechanism of its opposite effect on locomotor activity in rats and mice. Eur J Pharmacol 26 (1974) 41-50
30. Lacey M.G., Mercuri N.B., and North R.A. Two cell types in rat substantia nigra zona compacta distinguished by membrane properties and the actions of dopamine and opioids. J Neurosci 9 (1989) 1233-1241
31. Laviolette S.R., and van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecules to behaviour. Nat Rev Neurosci 5 (2004) 55-65
32. Liu Z.H., and Jin W.Q. Decrease of ventral tegmental area dopamine neuronal activity in nicotine withdrawal rats. Neuroreport 15 (2004) 1479-1481
33. Mello N.K., Mendelson J.H., Sellers M.L., and Kuehnle J.C. Effects of heroin self-administration on cigarette smoking. Psychopharmacology (Berl) 67 (1980) 45-52
34. Michaluk J., Antkiewicz-Michaluk L., Rokosz-Pelc A., and Vetulani J. Opiate and alpha 1-adrenergic receptors in mice responding to morphine with sedation or with running fit. Pol J Pharmacol Pharm 43 (1991) 115-119
35. Mijatovic J., Vihavainen T., Piepponen T.P., and Ahtee L. Withdrawal from chronic nicotine sensitizes mice to the striatal DA metabolism enhancing effect of acute morphine. Proceedings of the European opioid conference. Visegrad, Hungary, April 4-7 (2004)
36. Nuutinen S., Ahtee L., and Tuominen R.K. Time and brain region specific up-regulation of low affinity neuronal nicotinic receptors during chronic nicotine administration in mice. Eur J Pharmacol 515 (2005) 83-89
37. Pekonen K., Karlsson C., Laakso I., and Ahtee L. Plasma nicotine and cotinine concentrations after chronic oral nicotine administration and challenge doses. Eur J Pharm Sci 1 (1993) 13-18
38. Piepponen T.P., Honkanen A., Kivastik T., Zharkovsky A., Turtia A., Mikkola J.A., et al. Involvement of opioid μ1-receptors in opioid-induced acceleration of striatal and limbic dopaminergic transmission. Pharmacol Biochem Behav 63 (1999) 245-252
39. Pietilä K., Lähde T., Attila M., Ahtee L., and Nordberg A. Regulation of nicotinic receptors in the brain of mice withdrawn from chronic oral nicotine treatment. Naunyn Schmiedebergs Arch Pharmacol 357 (1998) 176-182
40. Rada P., Jensen K., and Hoebel B.G. Effects of nicotine and mecamylamine-induced withdrawal on extracellular dopamine and acetylcholine in the rat nucleus accumbens. Psychopharmacology (Berl) 157 (2001) 105-110
41. Richter K.P., Ahluwalia H.K., Mosier M.C., Nazir N., and Ahluwalia J.S. A population-based study of cigarette smoking among illicit drug users in the United States. Addiction 97 (2002) 861-869
42. Risso F., Parodi M., Grilli M., Molfino F., Raiteri M., and Marchi M. Chronic nicotine causes functional upregulation of ionotropic glutamate receptors mediating hippocampal noradrenaline and striatal dopamine release. Neurochem Int 44 (2004) 293-301
43. Robinson T.E., and Berridge K.C. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Brain Res Rev 18 (1993) 247-291
44. Rowell P.P. Effects of nicotine on dopaminergic neurotransmission. In: Levin E.D. (Ed). Nicotinic receptors in the nervous system. 1st ed. (2002), CRC Press, New York 51-80
45. Schmitz J.M., Grabowski J., and Rhoades H. The effects of high and low doses of methadone on cigarette smoking. Drug Alcohol Depend 34 (1994) 237-242
46. Tao R., and Auerbach S.B. Involvement of the dorsal raphe but not median raphe nucleus in morphine-induced increases in serotonin release in the rat forebrain. Neuroscience 68 (1995) 553-561
47. Taylor R.C., Harris N.A., Singleton E.G., Moolchan E.T., and Heishman S.J. Tobacco craving: intensity-related effects of imagery scripts in drug abusers. Exp Clin Psychopharmacol 8 (2000) 75-87
48. Vanderschuren L.J., De Vries T.J., Wardeh G., Hogenboom F.A., and Schoffelmeer A.N. A single exposure to morphine induces long-lasting behavioural and neurochemical sensitization in rats. Eur J Neurosci 14 (2001) 1533-1538
49. Vihavainen T., Gäddnäs H., Nuutinen S., Tuominen R.K., and Ahtee L. Withdrawal from 7-week chronic nicotine treatment sensitises mice to locomotor stimulant effects of morphine. Proceedings of the European opioid conference. Visegrad, Hungary, April 4-7 (2004)
50. Vihavainen T., Tuominen R.K., and Ahtee L. Effects of morphine and cocaine on locomotor activity in nicotine-withdrawn mice. Proceedings of the 11th European behavioural pharmacology meeting. Barcelona, Spain, September 9-12 (2005)
51. Walters C.L., Cleck J.N., Kuo Y.C., and Blendy J.A. μ-Opioid receptor and CREB activation are required for nicotine reward. Neuron 46 (2005) 933-943
52. Westerink B.H., Kwint H.F., and deVries J.B. The pharmacology of mesolimbic dopamine neurons: a dual-probe microdialysis study in the ventral tegmental area and nucleus accumbens of the rat brain. J Neurosci 16 (1996) 2605-2611
53. Wewers M.E., Dhatt R., and Tejwani G.A. Naltrexone administration affects ad libitum smoking behavior. Psychopharmacology (Berl) 140 (1998) 185-190
54. Wewers M.E., Dhatt R.K., Snively T.A., and Tejwani G.A. The effect of chronic administration of nicotine on antinociception, opioid receptor binding and met-enkelphalin levels in rats. Brain Res 822 (1999) 107-113
55. Wong G.Y., Wolter T.D., Croghan G.A., Croghan I.T., Offord K.P., and Hurt R.D. A randomized trial of naltrexone for smoking cessation. Addiction 94 (1999) 1227-1237
56. 2 receptors. Naunyn Schmiedebergs Arch Pharmacol 366 (2002) 276-281
57. Yoo J.H., Lee S.Y., Loh H.H., Ho I.K., and Jang C.G. Loss of nicotine-induced behavioral sensitization in μ-opioid receptor knockout mice. Synapse 51 (2004) 219-223
58. Zarrindast M.R., Barghi-Lashkari S., and Shafizadeh M. The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice. Pharmacol Biochem Behav 68 (2001) 283-289
59. Zarrindast M.R., Faraji N., Rostami P., Sahraei H., and Ghoshouni H. Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice. Pharmacol Biochem Behav 74 (2003) 363-369
60. Zarrindast M.R., and Farzin D. Nicotine attenuates naloxone-induced jumping behaviour in morphine-dependent mice. Eur J Pharmacol 298 (1996) 1-6
61. Zarrindast M.R., Khoshayand M.R., and Shafaghi B. The development of cross-tolerance between morphine and nicotine in mice. Eur Neuropsychopharmacol 9 (1999) 227-233